ProCE Banner Activity

PERSIST-1: Pacritinib Improved Spleen Volume Reductions in Myelofibrosis vs Best Available Therapy

Slideset Download
Conference Coverage
In this phase III study, pacritinib demonstrated significantly reduced total symptom scores and improved overall survival.

Released: June 05, 2015

Expiration: June 03, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation